If we want to get fine grained, when I say MGC's previous track record I'm referring to their 'distribution agreement' from 2017 with HL Pharma that has not resulted in any product changing hands and still hasn't been touched on by MGC since the initial announcement of the agreement, it's been over 18 months at this point.
Sure Mexacare will work directly with doctors, your quote also specifically mentions they will work with pharmacies as well. The money is in the large volumes being dished out to pharmacies, this is where the bigger volumes will start to be distributed from Mexacare's stockpiles and will cause Mexacare to keep coming back to MGC for more product. Focusing on one-on-one doctor to patient prescriptions where the doctor has to individually approve and supply the medicines to patients is very low level in terms of revenue generation for MGC.
The KPI's you speak of have not been agreed upon as of yet if I've read the announcement correctly "The obligations of exclusivity shall be subject to the Mexacare's compliance with the annualkey performance indicators to be agreed by the parties on an annual basis". Who knows if they'll set the bar low or high at this stage.
PS. Mexacare has not submitted a supply order to MGC yet as far as I am aware, so we are both getting very much ahead of ourselves.
MXC Price at posting:
5.6¢ Sentiment: Sell Disclosure: Not Held
